CD69 downregulates autoimmune reactivity through active transforming growth factor-β production in collagen-induced arthritis

Journal of Clinical Investigation

Volumn 112, Issue 6, 2003, Pages 872-882

  Sancho, David ^a   Gómez, Manuel ^a   Viedma, Fernando ^a   Esplugues, Enric ^b   Gordón Alonso, Mónica ^a   García López, María Angeles ^a   De La Fuente, Hortensia ^a   Martínez A, Carlos ^a   Lauzurica, Pilar ^b   Sánchez Madrid, Francisco ^a,c  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; COLLAGEN TYPE 2; CYTOKINE; INTERLEUKIN 1BETA; MESSENGER RNA; RANTES; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; LEUKOCYTE ANTIGEN; T LYMPHOCYTE ANTIGEN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL MODEL; ARTHRITIS; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; DISEASE SEVERITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; C57BL MOUSE; CYTOLOGY; FOOT; GENETICS; HUMAN; IMMUNOLOGY; JOINT; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; SPLEEN; SYNOVIAL FLUID;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNITY; CYTOKINES; DOWN-REGULATION; FOOT; HUMANS; INFLAMMATION; JOINTS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SPLEEN; SYNOVIAL FLUID; TRANSFORMING GROWTH FACTOR BETA;

EID: 0142217899     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200319112     Document Type: Article

References (59)

1. Hara, T., Jung, L.K., Bjorndahl, J.M., and Fu, S.M. 1986. Human T cell activation. III. Rapid induction of a phosphorylated 28 kD/32 kD disulfide-linked early activation antigen (EA1) by 12-o-terradecanoyl phorbol-13-acetate, mitogens, and antigens. J. Exp. Med. 164:1988-2005.
2. Cosulich, M.E., Rubartelli, A., Risso, A., Cozzolino, F., and Bargellesi, A. 1987. Functional characterization of an antigen involved in an early step of T-cell activation. Proc. Natl. Acad. Sci. U. S. A. 84:4205-4209.
3. Cebrian, M., et al. 1988. Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes. J. Exp. Med. 168:1621-1637.
4. Testi, R., D'Ambrosio, D., De Maria, R., and Santoni, A. 1994. The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol. Today. 15:479-483.
5. Sancho, D., Yanez-Mo, M., Tejedor, R., and Sanchez-Madrid, F. 1999. Activation of peripheral blood T cells by interaction and migration through endothelium: role of lymphocyte function antigen-1/intercellular adhesion molecule-1 and interleukin-15. Blood. 93:886-896.
6. Sanchez-Mateos, P., et al. 1989. Expression of a gp33/27,000 Mw activation inducer molecule (AIM) on human lymphoid tissues. Induction of cell proliferation on thymocytes and B lymphocytes by anti-AIM antibodies. Immunology. 68:72-79.
7. Laffon, A., et al. 1991. Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J. Clin. Invest. 88:546-552.
8. + T lymphocytes in viral chronic active hepatitis. Gastroenterology. 98:1029-1035.
9. Testi, R., Phillips, I.H., and Lanier, L.L. 1989. T cell activation via Leu-23 (CD69). J. Immunol. 143:1123-1128.
10. Feng, C., et al. 2002. A potential role for CD69 in thymocyte emigration. Int. Immunol. 14:535-544.
11. Nakayama, T., et al. 2002. The generation of mature, single-positive thymocytes in vivo is dysregulated by CD69 blockade or overexpression. J. Immunol. 168:87-94.
12. Lauzurica, P., et al. 2000. Phenotypic and functional characteristics of hematopoietic cell lineages in CD69-deficient mice. Blood. 95:2312-2320.
13. Esplugues, E., et al. 2003. Enhanced antitumor immunity in mice deficient in CD69. J. Exp. Med 197:1093-1106.
14. Myers, L.K., Rosloniec, E.F., Cremer, M.A., and Kang, A.H. 1997. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci. 61:1861-1878.
15. O'Shea, J.J., Ma, A., and Lipsky, P. 2002. Cytokines and autoimmunity. Nat. Rev. Immunol. 2:37-45.
16. Shull, M.M., et al. 1992. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 359:693-699.
17. Kulkarni, A.B., et al. 1993. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. U. S. A. 90:770-774.
18. Gorelik, L., and Flavell, R.A. 2001. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat. Med. 7:1118-1122.
19. Letterio, J.J., and Roberts, A.B. 1998. Regulation of immune responses by TGF-beta. Annu. Rev. Immunol. 16:137-161.
20. Kuruvilla, A.P., et al. 1991. Protective effect of transforming growth factor β1 on experimental autoimmune disease in mice. Proc. Natl. Acad. Sci. U. S. A. 88:2918-2921.
21. Brandes, M.E., Allen, J.B., Ogawa, Y., and Wahl, S.M. 1991. Transforming growth factor β1 suppresses acute and chronic arthritis in experimental animals. J. Clin. Invest. 87:1108-1113.
22. Allen, J.B., et al. 1990. Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta. J. Exp. Med. 171:231-247.
23. Prud'homme, G.J., and Piccirillo, C.A. 2000. The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases. J. Autoimmun. 14:23-42.
24. b) mice: new insights into an important disease model of rheumatoid arthritis. Eur. J. Immunol. 30:1568-1575.
25. Campbell, I.K., et al. 1998. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J. Immunol. 161:3639-3644.
26. Butler, D.M., et al. 1997. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J. Immunol. 159:2867-2876.
27. Arnett, F.C., et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315-324.
28. Dasch, J.R., Pace, D.R., Waegell, W., Inenaga, D., and Ellingsworth, L.R. 1989. Monoclonal antibodies recognizing transforming growth factor beta (TGF-β): bioactivity, neutralization and TGF-β2 affinity purification. J. Immunol. 142:1536-1541.
29. Lubberts, E., Joosten, L.A., van de Loo, F.A., van den Gerssetaar, L.A., and van den Berg, W.B. 2000. Reduction of interleukin-17-induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin-4. Arthritis Rheum. 43:1300-1306.
30. Sancho, D., et al. 2000. Functional analysis of ligand-binding and signal transduction domains of CD69 and CD23 C-type lectin leukocyte receptors. J. Immunol. 165:3868-3875.
31. Feldmann, M., Brennan, F.M., and Maini, R.N. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14:397-440.
32. Campbell, I.K., O'Donnell, K., Lawlor, K.E., and Wicks, I.P. 2001. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J. Clin. Invest. 107:1519-1527.
33. Kehrl, J.H., et al. 1986. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 163:1037-1050.
34. Griffiths, M.M., Encinas, J.A., Remmers, E.F., Kuchroo, V.K., and Wilder, R.L. 1999. Mapping autoimmunity genes. Curr. Opin. Immunol. 11:689-700.
35. Wandstrat, A., and Wakeland, E. 2001. The genetics of complex autoimmune diseases: non-MHC susceptibility genes. Nat. Immunol. 2:802-809.
36. Remmers, E.F., et al. 1996. A genome scan localizes five non-MHC loci controlling collagen-induced arthritis in rats. Nat. Genet. 14:82-85.
37. Mc Indoe, R.A., Bohlman, B., Chi, E., Schuster, E., and Lindhardt, M. 1999. Localization of non-MHC collagen-induced arthritis susceptibility loci in DBA/1j mice. Proc. Natl. Acad. Sci. U. S. A. 96:2210-2214.
38. Lopez-Cabrera, M., et al. 1993. Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J. Exp. Med. 178:537-547.
39. Ziegler, S.F., et al. 1993. Molecular characterization of the early activation antigen CD69: a type II membrane glycoprotein related to a family of natural killer cell activation antigens. Eur. J. Immunol. 23:1643-1648.
40. Watson, W.C., and Townes, A. 1985. Genetic susceptibility to murine collagen II autoimmune arthritis. Proposed relationship to the IgG2 autoantibody subclass response, complement C5, major histocompatibility complex (MHC), and non-MHC loci. J. Exp. Med. 162:1878-1891.
41. Feldmann, M. 2002. Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2:364-371.
42. Williams, R.O., Marinova-Mutafchieva, L., Feldmann, M., and Maini, R.N. 2000. Evaluation of TNF-α and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-α/anti-CD4 therapy. J. Immunol. 165:7240-7245.
43. Ji, H., et al. 2002. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J. Exp. Med. 196:77-85.
44. Maini, R.N., et al. 1999. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 354:1932-1939.
45. Weinblatt, M.E., et al. 1999. A trial on etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340:253-259.
46. Hallegua, D.S., and Weisman, M.H. 2002. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann. Rheum. Dis. 61:960-967.
47. Chen, Y., Kuchroo, V.K., Inobe, J., Hafler, D.A., and Weiner, H.L. 1994. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 265:1237-1240.
48. + T cells. J. Exp. Med. 183:2669-2674.
49. Piccirillo, C.A., Chang, Y., and Prud'homme, G.J. 1998. Transforming growth factor beta-1 (TGF-β1) somatic gene therapy prevents autoimmune disease in NOD mice. J. Immunol. 161:3950-3956.
50. Gorelik, L., and Flavell, R.A. 2000. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 12:171-181.
51. Cazac, B.B., and Roes, J. 2000. TGF-β receptor controls B cell responsiveness and induction of IgA in vivo. Immunity. 13:443-451.
52. Walunas, T.L., et al. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1:405-413.
53. + T cells. J. Exp. Med. 188:1849-1857.
54. Santis, A.G., et al. 1992. Tumor necrosis factor-alpha production induced in T lymphocytes through the AIM/CD69 activation pathway. Eur. J. Immunol. 22:1253-1259.
55. McInnes, I.B., Leung, B.P., Sturrock, R.D., Field, M., and Liew, F.Y. 1997. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat. Med. 3:189-195.
56. Hernández-García, C., Fernández-Gutiérrez, B., Morado, I.C., Bañares, A.A., and Jover, J.A. 1996. The CD69 activation pathway in rheumatoid arthritis synovial fluid T cells. Arthritis Rheum. 39:1277-1286.
57. Fava, R., Olsen, N., Keski-Oja, J., Moses, H., and Pincus, T. 1989. Active and latent forms of transforming growth factor β activity in synovial effusions. J. Exp. Med. 169:291-296.
58. Wahl, S.M., Allen, J.B., Wong, H.L., Dougherty, S.F., and Ellingsworth, J.R. 1990. Antagonistic and agonistic effects of transforming growth factor-beta and IL-1 in rheumatoid synovium. J. Immunol. 145:2514-2519.
59. Yu, X., et al. 2001. Anti-CD69 autoantibodies cross-react with low density lipoprotein receptor-related protein 2 in systemic autoimmune diseases. J. Immunol. 166:1360-1369.